Highlights:

• FY26 revenue increased 11% to AU$377.5 million, while NPAT declined 5% to AU$40.2 million.
• FY27 guidance points to revenue of AU$540–580 million and NPAT of AU$54–58 million.
• A substantial pipeline and growing Americas exposure could provide further support for future growth.

Strong FY26 Revenue Sets the Stage

Lycopodium Limited (ASX: LYL) delivered its FY2026 results on 19 August 2026, with the engineering and project delivery specialist outlining a potentially stronger earnings trajectory ahead. Its share price climbed to AU$21.20, gaining AU$2.379 or 12.646%, as investors responded to the company’s outlook and expanding project pipeline.

For FY26, revenue rose 11% year-on-year to AU$377.5 million, although EBITDA fell 13% to AU$59.5 million and NPAT declined 5% to AU$40.2 million. EPS decreased 5% to 101.1 cents per share. Despite the softer profitability, Lycopodium maintained a strong financial position, ending the period with AU$106.2 million in cash, minimal debt and NTA of AU$3.92 per share.

The Numbers That Could Change the Story

The major focus now shifts to FY27. Lycopodium has provided revenue guidance of AU$540 million to AU$580 million and NPAT guidance of AU$54 million to AU$58 million. At the midpoint, this represents approximately 50% revenue growth and 40% NPAT growth compared with FY26.

The company enters the new financial year with more than 90 resource studies, AU$661 million in committed contracts and an estimated AU$1.4 billion revenue opportunity pipeline. It also has AU$4.9 billion of managed project capital expenditure in delivery.

Americas Expansion Adds Another Growth Layer

Lycopodium is also strengthening its presence across the Americas. The company said the region accounted for approximately 11% of total revenue, with activity expanding across Canada, Peru, Argentina, Brazil and the US. More than five countries are currently represented in its tendering pipeline, supporting its longer-term diversification strategy.

With major project wins, a growing pipeline and ambitious FY27 guidance, the question now is whether Lycopodium can convert this expanding opportunity set into another significant earnings step-up.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au